TABLE 1.
Sample Selection
| Commercial n (%) | Medicaid n (%) | Medicare n (%) | Total n (%) | |
|---|---|---|---|---|
| Health plan enrollees between September 1, 2007, and March 31, 2013 (January 1, 2007, and December 31, 2012, for Medicare) | 7,651,159 (100.0) | 1,246,146 (100.0) | 13,314,377 (100.0) | 22,211,682 (100.0) |
| Aged ≥ 18 years | 7,186,364 (93.9) | 1,048,683 (84.2) | 12,317,405 (92.5) | 20,552,452 (92.5) |
| Oral atypical antipsychotic prescription claim | 653,483 (8.5) | 288,269 (23.1) | 557,038 (4.2) | 1,498,790 (6.8) |
| Patients with ≥ 1 inpatient or ≥ 2 outpatient claims with ICD-9-CM diagnosis code for BPD (296.0x-296.1x, 296.4x-296.8x), MDD (296.2x-296.3x, 311.x), or schizophrenia (295.x) during the 6-month pre-index prescription period | 298,670 (3.9) | 136,294 (10.9) | 40,653 (0.3) | 475,617 (2.1) |
| Continuous enrollment for ≥ 18 months (6 months pre- and 12 months post-antipsychotic initiation) | 133,303 (1.7) | 74,634 (5.9) | 16,520 (0.1) | 224,457 (1.0) |
| Exclude patients who received index prescription via mail order or where the oral atypical wasn’t the first antipsychotic | 106,877 (1.4) | 67,317 (5.4) | 12,922 (0.1) | 187,116 (0.8) |
| Exclude patients who switched to a long-acting injectable or whose index prescription was for clozapine | 106,424 (1.4) | 65,277 (5.2) | 12,878 (0.1) | 184,579 (0.8) |
| Patients with a schizophrenia diagnosis | 5,521 (0.0) | 22,516 (1.8) | 1,570 (0.0) | 29,607 (0.1) |
BPD = bipolar disorder; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; MDD = major depressive disorder.